Operaciones de insiders

EDGAR

Taysha Gene Therapies, Inc.

Operaciones informadas por directores, ejecutivos y titulares de más del 10 % en los Formularios 3, 4 y 5 de la SEC, leídas del XML de cada presentación. Los códigos y su redacción son los de la SEC.

El Formulario 4 debe presentarse dentro de los dos días hábiles posteriores a la operación, por lo que las más recientes pueden no estar presentadas aún.

Ventana: operaciones con fecha desde el 16 nov 2025.

Compras en el mercado abierto (código P)
0 operaciones, — acciones
Ventas en el mercado abierto (código S)
12 operaciones, 1.368.795 acciones
Suma de acciones × precio por acción: 6.658.093,26

Los totales suman las operaciones presentadas que se listan; cuentan lo informado y no miden una dirección.

Mostrando 1–38 de 38

Operaciones de insiders, las más recientes primero, según los Formularios 3, 4 y 5 de la SEC
FechaTitular informanteCódigoAdquirido o enajenadoAccionesPrecio por acción, según lo presentadoValor (derivado)Acciones poseídas despuésDirecta o indirectaCasilla de la Regla 10b5-1NotasFuente
10 jul 2026 Presentado el 10 jul 2026Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)200.0006,24
1.248.000

Derivado: acciones × precio por acción. Valor exacto 1248000.00.

936.410Directa (D) Sí
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Abrir presentación 0001665124-26-000013 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 2 jun 2026Long Alison S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)21.3350—127.178Directa (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir presentación 0001891712-26-000002 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 2 jun 2026Long Alison S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (42.671) — precio de ejercicio 5.97
Adquirido (A)42.6710—42.671Directa (D) No
F2
  • F2 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir presentación 0001891712-26-000002 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 2 jun 2026Sepp-Lorenzino Laura Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)21.3350—127.178Directa (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir presentación 0001777421-26-000005 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 2 jun 2026Sepp-Lorenzino Laura Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (42.671) — precio de ejercicio 5.97
Adquirido (A)42.6710—42.671Directa (D) No
F2
  • F2 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir presentación 0001777421-26-000005 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 2 jun 2026Donenberg Phillip B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)21.3350—241.289Directa (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir presentación 0001238120-26-000008 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 2 jun 2026Donenberg Phillip B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (42.671) — precio de ejercicio 5.97
Adquirido (A)42.6710—42.671Directa (D) No
F2
  • F2 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir presentación 0001238120-26-000008 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 2 jun 2026Stalfort John A III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)21.3350—1.176.559Directa (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir presentación 0001709418-26-000002 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 2 jun 2026Stalfort John A III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (42.671) — precio de ejercicio 5.97
Adquirido (A)42.6710—42.671Directa (D) No
F3
  • F3 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir presentación 0001709418-26-000002 Leído del XML de la presentación Disputar esta fila
10 abr 2026 Presentado el 13 abr 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)19.0211,71
32.525,91

Derivado: acciones × precio por acción. Valor exacto 32525.91.

1.336.410Directa (D) Sí— Abrir presentación 0001665124-26-000011 Leído del XML de la presentación Disputar esta fila
10 abr 2026 Presentado el 13 abr 2026Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)200.0004,46
892.000

Derivado: acciones × precio por acción. Valor exacto 892000.00.

1.136.410Directa (D) Sí
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Abrir presentación 0001665124-26-000011 Leído del XML de la presentación Disputar esta fila
10 abr 2026 Presentado el 13 abr 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor derivado: Employee Stock Option (right to buy) — subyacente Common Stock (19.021) — precio de ejercicio 1.71
Enajenado (D)19.0210—455.920Directa (D) Sí
F3
  • F3 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001665124-26-000011 Leído del XML de la presentación Disputar esta fila
4 feb 2026 Presentado el 6 feb 2026Alam Kamran Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)16554,52
7480,6

Derivado: acciones × precio por acción. Valor exacto 7480.60.

1.442.131Directa (D) No
F1
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
Abrir presentación 0001793412-26-000012 Leído del XML de la presentación Disputar esta fila
26 ene 2026 Presentado el 27 ene 2026Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)26.9184,61
124.091,98

Derivado: acciones × precio por acción. Valor exacto 124091.98.

1.317.389Directa (D) No
F1, F3
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
Abrir presentación 0001665124-26-000008 Leído del XML de la presentación Disputar esta fila
26 ene 2026 Presentado el 27 ene 2026Nolan Sean P. Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)41.3124,61
190.448,32

Derivado: acciones × precio por acción. Valor exacto 190448.32.

2.908.257Directa (D) No
F1, F3
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
Abrir presentación 0001569926-26-000008 Leído del XML de la presentación Disputar esta fila
26 ene 2026 Presentado el 27 ene 2026Alam Kamran Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)23.8494,61
109.943,89

Derivado: acciones × precio por acción. Valor exacto 109943.89.

1.443.786Directa (D) No
F1, F3
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
Abrir presentación 0001793412-26-000008 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 27 ene 2026Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)89.1324,75
423.377

Derivado: acciones × precio por acción. Valor exacto 423377.00.

1.344.307Directa (D) No
F1, F2
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
Abrir presentación 0001665124-26-000008 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 27 ene 2026Nolan Sean P. Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)136.7894,75
649.747,75

Derivado: acciones × precio por acción. Valor exacto 649747.75.

2.949.569Directa (D) No
F1, F2
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
Abrir presentación 0001569926-26-000008 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 27 ene 2026Alam Kamran Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)78.9684,75
375.098

Derivado: acciones × precio por acción. Valor exacto 375098.00.

1.467.635Directa (D) No
F1, F2
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
Abrir presentación 0001793412-26-000008 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Nolan Sean P. Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)1.008.0000—3.086.358Directa (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001569926-26-000002 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Nolan Sean P. Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Employee Stock Option (right to buy) — subyacente Common Stock (648.000) — precio de ejercicio 4.86
Adquirido (A)648.0000—648.000Directa (D) No
F3
  • F3 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001569926-26-000002 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)111.3240,6989
77.804,3436

Derivado: acciones × precio por acción. Valor exacto 77804.3436.

1.117.763Directa (D) Sí— Abrir presentación 0001665124-26-000002 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)88.6761,71
151.635,96

Derivado: acciones × precio por acción. Valor exacto 151635.96.

1.206.439Directa (D) Sí— Abrir presentación 0001665124-26-000002 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)200.0004,71
942.000

Derivado: acciones × precio por acción. Valor exacto 942000.00.

1.006.439Directa (D) Sí
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Abrir presentación 0001665124-26-000002 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Nagendran Sukumar Director · Officer: President and Head of RD
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)427.0000—1.433.439Directa (D) Sí
F3
  • F3 Represents a restricted stock unit (RSU) award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001665124-26-000002 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor derivado: Employee Stock Option (right to buy) — subyacente Common Stock (111.324) — precio de ejercicio 0.6989
Enajenado (D)111.3240—111.359Directa (D) Sí
F4
  • F4 The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001665124-26-000002 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor derivado: Employee Stock Option (right to buy) — subyacente Common Stock (88.676) — precio de ejercicio 1.71
Enajenado (D)88.6760—474.941Directa (D) Sí
F5
  • F5 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001665124-26-000002 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Nagendran Sukumar Director · Officer: President and Head of RD
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Employee Stock Option (right to buy) — subyacente Common Stock (274.000) — precio de ejercicio 4.86
Adquirido (A)274.0000—274.000Directa (D) Sí
F6
  • F6 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001665124-26-000002 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Alam Kamran Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)359.0000—1.546.603Directa (D) No
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001793412-26-000002 Leído del XML de la presentación Disputar esta fila
12 ene 2026 Presentado el 14 ene 2026Alam Kamran Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Employee Stock Option (right to buy) — subyacente Common Stock (231.000) — precio de ejercicio 4.86
Adquirido (A)231.0000—231.000Directa (D) No
F2
  • F2 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001793412-26-000002 Leído del XML de la presentación Disputar esta fila
1 dic 2025 Presentado el 1 dic 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)260.0471,71
444.680,37

Derivado: acciones × precio por acción. Valor exacto 444680.37.

1.266.486Directa (D) No— Abrir presentación 0001665124-25-000003 Leído del XML de la presentación Disputar esta fila
1 dic 2025 Presentado el 1 dic 2025Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)260.0474,51
1.172.811,97

Derivado: acciones × precio por acción. Valor exacto 1172811.97.

1.006.439Directa (D) No
F2
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive.
Abrir presentación 0001665124-25-000003 Leído del XML de la presentación Disputar esta fila
1 dic 2025 Presentado el 1 dic 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor derivado: Employee Stock Option (right to buy) — subyacente Common Stock (260.047) — precio de ejercicio 1.71
Enajenado (D)260.0470—563.617Directa (D) No
F4
  • F4 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001665124-25-000003 Leído del XML de la presentación Disputar esta fila
28 nov 2025 Presentado el 1 dic 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)70.1720,6989
49.043,2108

Derivado: acciones × precio por acción. Valor exacto 49043.2108.

1.076.611Directa (D) No— Abrir presentación 0001665124-25-000003 Leído del XML de la presentación Disputar esta fila
28 nov 2025 Presentado el 1 dic 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)39.9531,71
68.319,63

Derivado: acciones × precio por acción. Valor exacto 68319.63.

1.116.564Directa (D) No— Abrir presentación 0001665124-25-000003 Leído del XML de la presentación Disputar esta fila
28 nov 2025 Presentado el 1 dic 2025Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)110.1254,75
523.093,75

Derivado: acciones × precio por acción. Valor exacto 523093.75.

1.006.439Directa (D) No
F1
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2).
Abrir presentación 0001665124-25-000003 Leído del XML de la presentación Disputar esta fila
28 nov 2025 Presentado el 1 dic 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor derivado: Employee Stock Option (right to buy) — subyacente Common Stock (70.172) — precio de ejercicio 0.6989
Enajenado (D)70.1720—222.683Directa (D) No
F3
  • F3 The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001665124-25-000003 Leído del XML de la presentación Disputar esta fila
28 nov 2025 Presentado el 1 dic 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor derivado: Employee Stock Option (right to buy) — subyacente Common Stock (39.953) — precio de ejercicio 1.71
Enajenado (D)39.9530—823.664Directa (D) No
F4
  • F4 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir presentación 0001665124-25-000003 Leído del XML de la presentación Disputar esta fila

Titulares institucionales (Formulario 13F)

No hay en el almacén ninguna posición del Formulario 13F atribuida a este emisor. Un titular aún sin vincular o sin presentar está ausente, no en cero.

Titulares del 5 % (Anexos 13D y 13G)

Aquí se leen los anexos presentados en el formato estructurado de la SEC (desde finales de 2024). Los anteriores son texto libre y no se leen.

Titulares del 5 %, el evento más reciente primero, según lo presentado
TitularPorcentaje de la claseAcciones en poderFecha del eventoFormularioFuente
RA Capital Management, L.P. Common Stock, $0.00001 par value per share9.932.886.242,0006/30/2026 Presentado el 14 ago 2026SCHEDULE 13G/AEnmienda 5Abrir presentación 0001231919-26-000928 Disputar esta fila
Peter Kolchinsky Common Stock, $0.00001 par value per share9.932.886.242,0006/30/2026 Presentado el 14 ago 2026SCHEDULE 13G/AEnmienda 5Abrir presentación 0001231919-26-000928 Disputar esta fila
Rajeev Shah Common Stock, $0.00001 par value per share9.932.886.242,0006/30/2026 Presentado el 14 ago 2026SCHEDULE 13G/AEnmienda 5Abrir presentación 0001231919-26-000928 Disputar esta fila
RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share9.932.886.242,0006/30/2026 Presentado el 14 ago 2026SCHEDULE 13G/AEnmienda 5Abrir presentación 0001231919-26-000928 Disputar esta fila
Morgan Stanley Common Stock5.116.244.33906/30/2026 Presentado el 13 ago 2026SCHEDULE 13G/AEnmienda 2Abrir presentación 0000895421-26-000269 Disputar esta fila
Morgan Stanley Capital Services LLC Common Stock5.016.001.13006/30/2026 Presentado el 13 ago 2026SCHEDULE 13G/AEnmienda 2Abrir presentación 0000895421-26-000269 Disputar esta fila
Vestal Point Capital, LP Common Stock, par value $0.00001 per share6.318.000.000,0003/31/2026 Presentado el 15 may 2026SCHEDULE 13G/AEnmienda 1Abrir presentación 0000902664-26-002553 Disputar esta fila
Ryan Wilder Common Stock, par value $0.00001 per share6.318.000.000,0003/31/2026 Presentado el 15 may 2026SCHEDULE 13G/AEnmienda 1Abrir presentación 0000902664-26-002553 Disputar esta fila
RTW Investments, LP Common Stock, par value $0.00001 per share7.020.689.084,0003/31/2026 Presentado el 15 may 2026SCHEDULE 13G/AEnmienda 5Abrir presentación 0001493215-26-000122 Disputar esta fila
Roderick Wong Common Stock, par value $0.00001 per share7.020.689.084,0003/31/2026 Presentado el 15 may 2026SCHEDULE 13G/AEnmienda 5Abrir presentación 0001493215-26-000122 Disputar esta fila
RTW Investments, LP Common Stock, par value $0.00001 per share8.323.407.133,0012/31/2025 Presentado el 17 feb 2026SCHEDULE 13G/AEnmienda 4Abrir presentación 0001493215-26-000050 Disputar esta fila
Roderick Wong Common Stock, par value $0.00001 per share8.323.407.133,0012/31/2025 Presentado el 17 feb 2026SCHEDULE 13G/AEnmienda 4Abrir presentación 0001493215-26-000050 Disputar esta fila
Vestal Point Capital, LP Common Stock, par value $0.00001 per share513.750.000,0012/31/2025 Presentado el 17 feb 2026SCHEDULE 13GAbrir presentación 0000902664-26-001081 Disputar esta fila
Ryan Wilder Common Stock, par value $0.00001 per share513.750.000,0012/31/2025 Presentado el 17 feb 2026SCHEDULE 13GAbrir presentación 0000902664-26-001081 Disputar esta fila
FMR LLC COMMON STOCK4.913.528.365,8712/31/2025 Presentado el 5 feb 2026SCHEDULE 13G/AEnmienda 10Abrir presentación 0000315066-26-000536 Disputar esta fila
Abigail P. Johnson COMMON STOCK4.913.528.365,8712/31/2025 Presentado el 5 feb 2026SCHEDULE 13G/AEnmienda 10Abrir presentación 0000315066-26-000536 Disputar esta fila
BlackRock, Inc. Common Stock6.517.852.29112/31/2025 Presentado el 21 ene 2026SCHEDULE 13G/AEnmienda 2Abrir presentación 0002012383-26-000794 Disputar esta fila
RA Capital Management, L.P. Common Stock, $0.00001 par value per share9.927.662.481,0009/30/2025 Presentado el 14 nov 2025SCHEDULE 13G/AEnmienda 4Abrir presentación 0001231919-25-000491 Disputar esta fila
Peter Kolchinsky Common Stock, $0.00001 par value per share9.927.662.481,0009/30/2025 Presentado el 14 nov 2025SCHEDULE 13G/AEnmienda 4Abrir presentación 0001231919-25-000491 Disputar esta fila
Rajeev Shah Common Stock, $0.00001 par value per share9.927.662.481,0009/30/2025 Presentado el 14 nov 2025SCHEDULE 13G/AEnmienda 4Abrir presentación 0001231919-25-000491 Disputar esta fila
RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share9.927.662.481,0009/30/2025 Presentado el 14 nov 2025SCHEDULE 13G/AEnmienda 4Abrir presentación 0001231919-25-000491 Disputar esta fila
Octagon Capital Advisors LP Common Stock, $0.00001 par value3.39.067.500,0009/30/2025 Presentado el 14 nov 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0001214659-25-016718 Disputar esta fila
Octagon Investments Master Fund Common Stock, $0.00001 par value3.39.067.500,0009/30/2025 Presentado el 14 nov 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0001214659-25-016718 Disputar esta fila
Ting Jia Common Stock, $0.00001 par value3.39.067.500,0009/30/2025 Presentado el 14 nov 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0001214659-25-016718 Disputar esta fila
RA Capital Management, L.P. Common Stock, $0.00001 par value per share9.925.345.988,0006/30/2025 Presentado el 14 ago 2025SCHEDULE 13G/AEnmienda 3Abrir presentación 0001415889-25-022033 Disputar esta fila
Peter Kolchinsky Common Stock, $0.00001 par value per share9.925.345.988,0006/30/2025 Presentado el 14 ago 2025SCHEDULE 13G/AEnmienda 3Abrir presentación 0001415889-25-022033 Disputar esta fila
Rajeev Shah Common Stock, $0.00001 par value per share9.925.345.988,0006/30/2025 Presentado el 14 ago 2025SCHEDULE 13G/AEnmienda 3Abrir presentación 0001415889-25-022033 Disputar esta fila
RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share9.925.345.988,0006/30/2025 Presentado el 14 ago 2025SCHEDULE 13G/AEnmienda 3Abrir presentación 0001415889-25-022033 Disputar esta fila
RTW Investments, LP Common Stock, par value $0.00001 per share9.925.183.287,0006/30/2025 Presentado el 14 ago 2025SCHEDULE 13G/AEnmienda 3Abrir presentación 0001415889-25-021712 Disputar esta fila
Roderick Wong Common Stock, par value $0.00001 per share9.925.183.287,0006/30/2025 Presentado el 14 ago 2025SCHEDULE 13G/AEnmienda 3Abrir presentación 0001415889-25-021712 Disputar esta fila
FMR LLC COMMON STOCK6.215.627.821,8706/30/2025 Presentado el 6 ago 2025SCHEDULE 13G/AEnmienda 9Abrir presentación 0000315066-25-002098 Disputar esta fila
Abigail P. Johnson COMMON STOCK6.215.627.821,8706/30/2025 Presentado el 6 ago 2025SCHEDULE 13G/AEnmienda 9Abrir presentación 0000315066-25-002098 Disputar esta fila
Morgan Stanley Common Stock6.716.858.64406/30/2025 Presentado el 6 ago 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0000895421-25-000463 Disputar esta fila
Morgan Stanley Capital Services LLC Common Stock5.614.095.14306/30/2025 Presentado el 6 ago 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0000895421-25-000463 Disputar esta fila
BlackRock, Inc. Common Stock5.213.153.32606/30/2025 Presentado el 16 jul 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0002052113-25-002549 Disputar esta fila
THE GOLDMAN SACHS GROUP, INC. Common Stock, par value $0.00001 per share5.112.748.968,0006/26/2025 Presentado el 3 jul 2025SCHEDULE 13GAbrir presentación 0000769993-25-000401 Disputar esta fila
GOLDMAN SACHS CO. LLC Common Stock, par value $0.00001 per share5.112.748.968,0006/26/2025 Presentado el 3 jul 2025SCHEDULE 13GAbrir presentación 0000769993-25-000401 Disputar esta fila

El porcentaje es de la clase que indica la presentación, según lo declaró el titular. Los miembros de un grupo informan cada uno las acciones del grupo, por lo que las filas no se suman.

Qué se leyó

2.093.437 presentaciones leídas, del 14 jun 2004 al 13 nov 2026: Formularios 3, 3/A, 4, 4/A, 5, 5/A.

Algunos años pueden estar incompletos mientras se sigue leyendo el archivo. Un año con pocas presentaciones aquí no afirma que se hicieran pocas.

Presentaciones leídas, por año de presentación
Año de presentaciónPresentaciones leídas
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
202240.015
2023199.811
2024186.415
2025235.520
2026254.737

Las presentaciones anteriores a que la SEC exigiera XML se listan, pero no se extraen.

Volver a Taysha Gene Therapies, Inc.